Posted on Nov 10, 2015, 6 a.m.
Long-term study shows benefits of growth hormone therapy for bone density persist for years, among postmenopausal women.
A progressive condition that causes bones to weaken, osteoporosis is a common experience-among postmenopausal women. Emily Krantz, from Sodra Alvsborgs Hospital (Sweden), and colleagues completed a decade-long study of growth hormone therapy for osteoporosis. During an 18-month-long randomized, double-blind trial, 80 postmenopausal women with osteoporosis received daily injections of either placebo, a single unit of growth hormone or a 2.5-unit dose of growth hormone. The women were between the ages of 50 and 70 when they were recruited at the study’s start. After 18 months, the women who received the placebo halted the injections. Women who received growth hormone continued to receive injections for another 18 months. The researchers continued to follow up with the women for seven years after the growth hormone treatment was halted to monitor their bone density, fractures and perception of their quality of life. The researchers compared the participants' bone density and rate of fractures to those of a group of 120 women who did not have osteoporosis (controls). A decade after the study began, the women who received the larger growth hormone dose still had higher bone mineral density levels than the participants who received the lower dose or the placebo. The rate of fractures in the treated women who had osteoporosis declined by 50% during the 10-year-long study. More than half of the participants had fractured bones prior to the start of the study. In contrast, the rate of fractures rose four-fold in the control group as some of those women were diagnosed with osteoporosis. The lead investigator observes that: "Our study is the largest and longest controlled study of growth hormone treatment for osteoporosis in postmenopausal women to date. Years after treatment stopped, women who were treated with growth hormone still experienced improved bone density and reduced fracture risk."
Krantz E, Trimpou P, Landin-Wilhelmsen K. “Effect of Growth Hormone Treatment on Fractures and Quality of Life in Postmenopausal Osteoporosis: A 10-Year Follow-Up Study.” J Clin Endocrinol Metab. 2015 Sep;100(9):3251-9.